is a Tokyo-based Japanese pharmaceutical company that develops and markets prescription and over-the-counter drug (OTC) products, especially throat and swallowing products.
In the early 18th century, "Ryukakusan" was a powdered Kampo cough medicine produced by the Fuji family, physicians to the Satake Clan of the Akita Domain. Literally "dragon antler powder", it was named after its ingredients: long gu ("dragon bone"), deer antler powder, and borneol. Shoteiji Fujii began selling it as medicine for the public in 1871. In 1894, his son Tokusaburo revised the formula, introducing the now-familiar herbal formulation in fine powder form.
In 1995, the company had a ÃÂ¥4 billion debt. They recovered from this by selling the Iatron Laboratory to Mitsubishi in 2002.
Ryukakusan's products are popular in China and Taiwan. Tourists buy their products in bulk, to bring home, when they travel to Japan.
Ryukakusan exploded in popularity in China in 2015 after a post named it as a "miraculous drug" for relief from sore throat caused by air pollution. In 2016, a Chinese person was arrested in Japan for suspicion of illegally purchasing the drug for resale. In 2017, Taobao delisted a number of Japanese drugs, including Ryukakusan, for not having proper authorization. In 2019, a copycat product Ryu-no-san appeared in China.